A pilot study of cognitive behavioural therapy integrated with activity pacing for fatigued breast cancer patients undergoing chemotherapy in Ethiopia.
breast cancer
cognitive behavioural therapy
depression
fatigue
pilot study
quality of life
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
01
2022
accepted:
24
08
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
11
10
2022
Statut:
epublish
Résumé
Fatigue is a common symptom in breast cancer patients, and it is one of the major factors that influence the quality of life (QoL). Cognitive behavioural therapy (CBT) has been recommended to manage cancer-related fatigue. In this study, CBT will be integrated with activity pacing (AP), which can help breast cancer patients achieve a balance between activity and rest. Therefore, this pilot study aimed to investigate the acceptability, feasibility, and efficacy of the CBT-AP intervention. A total of 10 fatigued breast cancer patients undergoing chemotherapy were included in the study. The acceptability and feasibility of the study were measured by the patient recruitment rate, attrition rate, intervention fidelity, intervention compliance, and therapist's and participant's evaluations of the intervention. The outcomes were measured at baseline and at 6 weeks of intervention. The pre-post study suggested that CBT-AP was found to be acceptable and feasible for fatigued breast cancer patients undergoing chemotherapy. Among 27 eligible participants, 10 (37.03%) participants accepted our invitation to participate in the study. One participant dropped out from the intervention because of serious illness, and the dropout rate was 10%.Both the intervention fidelity and intervention compliance were found to be satisfactory.Fatigue severity [Brief Fatigue Inventory (BFI)] was reduced in 77.77% of participants from baseline to 6 weeks of intervention. The global health status/QoL scale and physical, emotional, and social functioning scales were improved from baseline to 6 weeks of intervention. All symptom scales, except constipation, diarrhea, and financial difficulties, were decreased after the intervention. Depression [Public Health Questionnaire (PHQ)-9] was reduced in 55.55% of participants. This study suggested that CBT-AP is an acceptable, feasible, and potentially efficacious intervention to reduce fatigue and improve the QoL of breast cancer patients. The efficacy of a CBT-AP programme is going to be investigated in subsequent larger randomized clinical trials.
Sections du résumé
Background
UNASSIGNED
Fatigue is a common symptom in breast cancer patients, and it is one of the major factors that influence the quality of life (QoL). Cognitive behavioural therapy (CBT) has been recommended to manage cancer-related fatigue. In this study, CBT will be integrated with activity pacing (AP), which can help breast cancer patients achieve a balance between activity and rest. Therefore, this pilot study aimed to investigate the acceptability, feasibility, and efficacy of the CBT-AP intervention.
Methods
UNASSIGNED
A total of 10 fatigued breast cancer patients undergoing chemotherapy were included in the study. The acceptability and feasibility of the study were measured by the patient recruitment rate, attrition rate, intervention fidelity, intervention compliance, and therapist's and participant's evaluations of the intervention. The outcomes were measured at baseline and at 6 weeks of intervention.
Results
UNASSIGNED
The pre-post study suggested that CBT-AP was found to be acceptable and feasible for fatigued breast cancer patients undergoing chemotherapy. Among 27 eligible participants, 10 (37.03%) participants accepted our invitation to participate in the study. One participant dropped out from the intervention because of serious illness, and the dropout rate was 10%.Both the intervention fidelity and intervention compliance were found to be satisfactory.Fatigue severity [Brief Fatigue Inventory (BFI)] was reduced in 77.77% of participants from baseline to 6 weeks of intervention. The global health status/QoL scale and physical, emotional, and social functioning scales were improved from baseline to 6 weeks of intervention. All symptom scales, except constipation, diarrhea, and financial difficulties, were decreased after the intervention. Depression [Public Health Questionnaire (PHQ)-9] was reduced in 55.55% of participants.
Conclusion
UNASSIGNED
This study suggested that CBT-AP is an acceptable, feasible, and potentially efficacious intervention to reduce fatigue and improve the QoL of breast cancer patients. The efficacy of a CBT-AP programme is going to be investigated in subsequent larger randomized clinical trials.
Identifiants
pubmed: 36212410
doi: 10.3389/fonc.2022.847400
pmc: PMC9533338
doi:
Types de publication
Journal Article
Langues
eng
Pagination
847400Informations de copyright
Copyright © 2022 Getu, Chen, Addissie, Seife, Wang and Kantelhardt.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Cancer. 2008 Nov 11;8:330
pubmed: 19014435
Breast Cancer Res Treat. 2019 Aug;176(3):519-533
pubmed: 31087199
Psychiatry Res. 2013 Dec 15;210(2):653-61
pubmed: 23972787
Sleep. 2020 Oct 13;43(10):
pubmed: 32274500
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Anticancer Agents Med Chem. 2022;22(4):801-810
pubmed: 34151769
Cancer. 2012 Apr 15;118(8 Suppl):2300-11
pubmed: 22488704
JAMA Oncol. 2017 Jul 01;3(7):961-968
pubmed: 28253393
BMC Cancer. 2015 Oct 23;15:765
pubmed: 26500019
BMC Cancer. 2021 May 22;21(1):588
pubmed: 34022838
BMC Cancer. 2015 Feb 21;15:77
pubmed: 25885168
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211032268
pubmed: 34282645
BMC Cancer. 2019 Aug 27;19(1):836
pubmed: 31455282
Breast. 2019 Apr;44:15-23
pubmed: 30580170
Support Care Cancer. 2020 Nov;28(11):5469-5478
pubmed: 32170441
Lancet. 2003 Aug 23;362(9384):640-50
pubmed: 12944066
PLoS One. 2019 Sep 20;14(9):e0222629
pubmed: 31539399
Trials. 2020 Mar 27;21(1):295
pubmed: 32216832
J Consult Clin Psychol. 2015 Aug;83(4):677-688
pubmed: 25939017
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Neuropsychiatr Dis Treat. 2018 Oct 10;14:2665-2673
pubmed: 30349264
BMC Med Res Methodol. 2010 Jul 16;10:67
pubmed: 20637084
Front Oncol. 2020 Oct 21;10:556718
pubmed: 33194622
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
J Pain Symptom Manage. 2018 Aug;56(2):264-272
pubmed: 29753101
Front Oncol. 2021 Nov 12;11:745280
pubmed: 34868943
Psychiatry Res. 2019 Jan;271:52-59
pubmed: 30469089
Cancer. 2017 Oct 1;123(19):3825-3834
pubmed: 28621820
Syst Rev. 2019 Dec 13;8(1):324
pubmed: 31836007
J Nurs Res. 2018 Aug;26(4):266-279
pubmed: 29360672
Eur J Oncol Nurs. 2021 Feb;50:101879
pubmed: 33338740
J Clin Oncol. 2006 Oct 20;24(30):4882-7
pubmed: 17050873
J Adv Nurs. 2008 Mar;61(6):664-75
pubmed: 18302607
South Med J. 2010 Jan;103(1):37-41
pubmed: 19996840
J Cancer Surviv. 2018 Aug;12(4):519-527
pubmed: 29651784
JMIR Cancer. 2017 Jul 04;3(2):e8
pubmed: 28676465
J Clin Oncol. 2017 Aug 10;35(23):2656-2665
pubmed: 28489508
BMJ. 2018 Apr 25;361:k1415
pubmed: 29695476
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419829573
pubmed: 30791739
Front Oncol. 2018 Jan 11;7:326
pubmed: 29376027
J Clin Sleep Med. 2019 Jan 15;15(1):129-137
pubmed: 30621831
Clin Infect Dis. 1994 Jan;18 Suppl 1:S105-10
pubmed: 8148435
Health Qual Life Outcomes. 2019 Nov 5;17(1):165
pubmed: 31690327
Ann Oncol. 2020 Feb;31(2):283-288
pubmed: 31959345
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Oncologist. 2007;12 Suppl 1:4-10
pubmed: 17573451
J Pain Symptom Manage. 2017 Jul;54(1):74-84
pubmed: 28502786
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006953
pubmed: 19160308